Kopran Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹211 Cr +79.2% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
K

Kopran Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Kopran Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹154Cr
+13.9% YoY
−34.2% QoQ
Net profit
₹7Cr
−10.1% YoY
−64.5% QoQ
Margin
10.27%
−0.2 pp YoY
−3.8 pp QoQ

Kopran Ltd Q1 FY27 key numbers

Revenue
Year-on-year growth in revenue (Q1): Rs. 15,399 Lakhs vs Rs. 13,522 Lakhs, approx. 14% increase.

As stated in Kopran Ltd's Q1 FY27 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Kopran Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹271
Market cap₹1.3K Cr
P/E53.7

The short version

Q1 FY 2026-27 revenue from operations: Rs. 15,399 Lakhs (Page 5). Q1 FY 2026-27 Figures (Rs. in Lakhs):.

From Kopran Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 FY 2026-27 revenue from operations: Rs. 15,399 Lakhs (Page 5)
  • Q1 FY 2025-26 revenue from operations: Rs. 13,522 Lakhs (Page 5)
  • Year-on-year growth in revenue (Q1): Rs. 15,399 Lakhs vs Rs. 13,522 Lakhs, approx. 14% increase
  • Sales/Other Income FY 2025-26: Rs. 68,177 Lakhs; Q1 FY 2026-27: Rs. 15,605 Lakhs (Page 20)
  • Formulations segment Q1 FY 2026-27 revenue: Rs. 5,709 Lakhs (Page 9-10)

2 more points from Kopran Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Kopran Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Focus on capacity expansion is highlighted as a strategic imperative (Page 15).
  • Development of an API and R&D facility at Panoli (Gujarat) is mentioned under strategic imperatives (Page 15).
  • Emphasis on process improvements, improving yields, and atomization of packing lines in formulations indicate operational enhancements but without specific capex figures or deadlines (Page 15).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.

Kopran Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Kopran Ltd Q1 FY27 results — key figures

Kopran Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue154135+13.9%234-34.2%
Operating profit (EBITDA)1614+11.9%33-52%
Operating margin10.27%10.45%-0.2 pp14.08%-3.8 pp
Profit before tax910-10.9%25-65.2%
Net profit (PAT)77-10.1%19-64.5%
EPS (₹)1.391.54-9.7%3.91-64.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Kopran Ltd Q1 FY27 results?

Q1 FY 2026-27 revenue from operations: Rs. 15,399 Lakhs (Page 5). Q1 FY 2026-27 Figures (Rs. in Lakhs):.

What is Kopran Ltd share price analysis?

Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.

Is Kopran Ltd planning capital expenditure?

Focus on capacity expansion is highlighted as a strategic imperative (Page 15). - Development of an API and R&D facility at Panoli (Gujarat) is mentioned under strategic imperatives (Page 15). - Emphasis on process improvements, improving yields, and atomization of packing lines in formulations indicate operational enhancements but without specific capex figures or deadlines (Page 15).

Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.